The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Safety and efficacy of plamotamab in the treatment of non-Hodgkin lymphoma subtypes
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, discusses some findings from a Phase I trial investigating the safety and efficacy of plamotamab, an anti-CD20 anti-CD3 bispecific antibody, in the treatment of patients with non-Hodgkin lymphoma (NHL). Dr Phillips highlights some of the results from this study, which found that plamotamab was effective in patients with various sub-types of NHL, including multiple relapsed diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). Dr Phillips also mentions that in some patients who have received chimeric antigen receptor T-cell (CAR-T) therapy, there have been good responses to plamotamab, and that further safety and efficacy data on step-up dosing regimens is needed. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
